ClinicalTrials.gg
RecruitingNCT05625204HIIT@HomeUpdated Dec 12, 2025

High Intensity Interval Training (HIIT) to Reduce Frailty and Enhance Resilience in Older Veterans

An interventional study of Center based attention (stretching only) control and Center based HIIT in Frailty, sponsored by VA Office of Research and Development. Recruiting at 2 sites in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-12.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Frailty by VA Office of Research and Development — 2 open to participants now, 5 under way, none of them phase 3. Frailty · VA Office of Research and Development.

Planned enrollment
3rd of 12
200 · median 59
Started
2024
with 1 other
No phase
9 of 12
2 open now
Registered
11th of 12
by date

Among the 12 studies in Frailty by VA Office of Research and Development, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2024, is one of 9 with no phase, and was the 11th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

2 of the 12 studies in Frailty by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Frailty by VA Office of Research and Development, or all of them as a file.
02

Study summary

Frailty is defined as a greater susceptibility to stressors resulting from age-related impairments in adaptive biological systems. Frailty leads to poorer physical performance and functional capacity and higher risk of adverse outcomes including falls, hospitalization, and mortality. Resilience, defined as the capacity to recover from disruptions to homeostasis, is critical to successful aging because it precedes frailty and enhances adults' ability to maintain optimal health and function well into older age. Evidence- based therapies to help older adults enhance resilience are limited and the biological underpinnings contributing to improved resilience have not yet been fully characterized. To address this important need, the investigators will conduct a clinical trial to examine the benefits of center- and home-based high intensity interval training (HIIT) on functional capacity, frailty, and resilience, and also to identify novel biomarkers of resilience in older Veterans.

Read the detailed description

Impact of Home-Based High Intensity Interval Training on Resilience in Older Veterans More than 30% of U.S. Veterans 65 years or older are frail, which is three-times higher than in non-Veterans in the same age group. Frailty is defined as an increased susceptibility to stressors resulting from age-related impairments in adaptive biological systems, leading to higher risk of adverse outcomes including falls, disability, hospitalization, and mortality. Further, frailty prevalence increases with age, affecting 50% of all adults 85 and over. Resilience, which is defined as the capacity to recover from stress-induced disruptions to homeostasis, is critical to successful aging because it precedes frailty and presents an opportunity to intervene on early health deficits, thus preventing aging-related decline in health, function, and quality of life. Evidence-based therapies that enhance resilience in older adults are limited and the complex biological and physiological mechanisms underlying resilience are not yet fully understood. Consequently, Veterans seeking to boost their ability to recover from late-life stressors and prevent frailty have few proven options. The investigators overarching aim is to characterize the complex factors contributing to resilience and develop novel strategies that enhance resilience to boost health span in older adults. Towards this end, the investigators previous VA RR\&D SPiRE Award allowed us to demonstrate the feasibility of 12-weeks of high intensity interval training (HIIT) among older Veterans. The investigators successfully enrolled and retained older male and female Veterans and safely conducted individually tailored HIIT that improved cardiorespiratory fitness, lower-body endurance, cognition, and quality of life. The purpose of the proposed larger trial is to build upon the investigators previous successes and develop and implement practical HIIT regimens to reduce frailty and enhance resilience in older Veterans. The investigators will conduct a randomized controlled trial to ascertain the therapeutic benefits of 12-weeks of center- and home-based HIIT on recovery and resilience among Veterans 60 years or older. The investigators have identified a series of biomarkers of resilience and are also seeking to examine key biological drivers of recovery at the molecular level. The investigators proposed study will not only identify feasible methods to measure resilience in older Veterans but will also assess the benefits of home-based HIIT on physical and cognitive performance, frailty, resilience, and health span.

03

Conditions studied

  • Frailty

Browse trials for

Keywords

  • aging
  • frailty
  • veteran
  • functional capacity
  • resilience
  • cognition
  • sleep
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 65 years and older
  • Male and female, any race
  • Medically cleared for exercise
  • Non-frail or pre-frail (frailty score \< 3)
  • Ability to use a recumbent exercise bike

Exclusion criteria

Exclusion Criteria:

  • Severe co-morbidity: (GOLD stage IV), CKD ( stage 3)), severe HTN (180 mmHg/120 mmHg)
  • VA-SLUMS score 20 or lower (Cognition)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Center based attention control

    Center based attention control

    Behavioral: Center based attention (stretching only) control

  • Experimental
    Center based HIIT

    Center based HIIT

    Behavioral: Center based HIIT

  • Experimental
    Home based HIIT

    Home based HIIT

    Behavioral: Home based HIIT

Interventions

  • BehavioralCenter based attention (stretching only) control

    Center based attention (stretching only) control

  • BehavioralCenter based HIIT

    Center based HIIT

  • BehavioralHome based HIIT

    Home based HIIT

06

What researchers measure

Primary outcomes

  1. Sub-maximal oxygen uptake test (VO2max)

    Participants are asked to exercise on an upright exercise bike as the resistance increases over time. During the exercise, participants are asked to breath through a mask that is connected to a oxygen and carbon dioxide measuring device. The assessment last for approximately 5-10 minutes and provides data the pertain to an individuals lung capacity, breathing rate, and endurance.

    Time frame: Change from baseline to endpoint at 12 weeks

Secondary outcomes

  1. Cognitive screen - SLUMS

    Cognitive status will be assessed using the VA - St. Louis University Mental Survey (VA-SLUMS) involving memory tests, shape recognition, and story recall. The survey scores range from 0-30, with a higher score representing greater cognitive capability. The investigators will also utilize the Cognivue to assess cognition. This is a combinatorial visual and reaction time test.

    Time frame: Change from baseline to endpoint at 12 weeks

  2. Amyloid beta 42/40 ratio

    Serum cognitive marker: change in amyloid beta 42/40 ratio (a unitless measure derived from the ratio of serum amyloid-beta 42 in picograms per milliliter divided by serum amyloid-beta 40 in picograms per milliliter) from baseline to endpoint after 12 weeks.

    Time frame: Change from baseline to endpoint at 12 weeks

  3. Cognitive screen - Cognivue

    Cognivue to assess cognition. This is a computer based combinatorial visual and reaction time test, which is scored 0 to 100.

    Time frame: Change from baseline to endpoint at 12 weeks

  4. Phosphorylated tau (P-tau)

    Serum cognitive marker: plasma levels of phosphorylated tau (P-tau) in picograms per milliliter from baseline to endpoint after 12 weeks.

    Time frame: Change from baseline to endpoint at 12 weeks

  5. Brain Derived Neurotrophic Factor (BDNF)

    Serum cognitive marker: change in Brain Derived Neurotrophic Factor (BDNF) in picograms per milliliter from baseline to endpoint after 12 weeks.

    Time frame: Change from baseline to endpoint at 12 weeks

  6. Fatigue

    Fatigue as assessed by the Brief Fatigue Inventory, which contains 9 self-rated questions with an aggregate score range of 0 to 90.

    Time frame: Change from baseline to endpoint at 12 weeks

  7. Sleep quantity and stages

    Objectively measure sleep quantity and stages using FITBIT Charge 5 actigraphy devices. These devices are worn on the wrist and sleep metrics, including total sleep time and time spent in light, deep, and REM sleep stages.

    Time frame: Change from baseline to endpoint at 12 weeks

  8. Sleep quality

    Sleep quality as assessed by Pittsburgh Sleep Quality Index (PSQI). The PSQI contains 19 self-rated questions that combined to form 7 component scores, each with a range of 0 to 3 points. These in turn are added to yield a global score with a range of 0 to 21 points.

    Time frame: Change from baseline to endpoint at 12 weeks

  9. Sleep chronotype

    Sleep chronotype as assessed by the Morningness/Eveningness survey, which contains 19 self-rated questions with an aggregate score range of 19 to 72.

    Time frame: Change from baseline to endpoint at 12 weeks

  10. Sleepiness

    Sleepiness as assessed by the Epworth Sleepiness Scale, which contains 8 self-rated questions with an aggregate score range of 0 to 24.

    Time frame: Change from baseline to endpoint at 12 weeks

  11. Insomnia

    Insomnia as assessed by the Insomnia Severity Index, which contains 7 self-rated questions with an aggregate score range of 0 to 28.

    Time frame: Change from baseline to endpoint at 12 weeks

  12. Anxiety and depression

    Anxiety and depression as assessed by the Hospital Anxiety and Depression Scale (HADS), which contains 14 self-rated questions with an aggregate score range of 0 to 21.

    Time frame: Change from baseline to endpoint at 12 weeks

  13. Sleep disorders

    Sleep disorders as assessed by the Holland Sleep Disorders Questionnaire, which contains 32 self-rated questions with an aggregate score range of 32 and 160.

    Time frame: Change from baseline to endpoint at 12 weeks

  14. 30 second chair rise test

    The investigators will measure endurance in participants by asking participants to sit and rise repeated from a chair as many times in a 30 second time frame.

    Time frame: Change from baseline to endpoint at 12 weeks

  15. Frailty assessment

    Frailty is a syndrome marked by greater susceptibility to adverse outcomes like falls and disability. The investigators will be using the Fried Frailty Phenotype that includes: 1) unexpected weight loss of 5% or more in the last year or BMI \< 18.5; score 0 or 1 if positive, 2) grip strength with BMI dependent cut points for men and women; score 0 or 1 if positive, 3) gait speed with height and sex dependent cutoffs; score 0 or 1 if positive, 4) activity assessed by a survey of the frequency of mild/moderate/energetic physical activity; score of 0 or 1, the latter if positive for hardly ever or never engaging in moderate or energetic physical activity, and 5) endurance assessed by survey of bed rest during the day; score of 0 or 1, the latter if occurring every day or every week. The composite score is therefore 0 to 5.

    Time frame: Change from baseline to endpoint at 12 weeks

  16. Gait speed

    Participants are asked to perform a timed walk of approximately 15 feet in length

    Time frame: Change from baseline to endpoint at 12 weeks

  17. Arm curl endurance

    Participants will receive a free weight (8lbs for men and 5lbs for women) and asked to perform total number of arm curls in 30 seconds while in a seated position.

    Time frame: Change from baseline to endpoint at 12 weeks

  18. Quality of life assessment

    Quality of life assessment is performed using the Quality of life, enjoyment, and satisfaction questionnaire - short form (Q-LES-Q-SF) survey instrument. The survey instrument scores from 0 to 70 with a greater score representing better quality of life.

    Time frame: Change from baseline to endpoint at 12 weeks

  19. Body Composition (Lean and fat mass)

    Body composition will be measured using bioelectric impedance (BIA) - a technique where participants are asked to stand on the measurement device and hold on to two metal handles. A light - and non-detectable - current is then transmitted allowing for collection of body fat and lean mass in the subject. The assessment takes roughly 2-3 minutes.

    Time frame: Change from baseline to endpoint at 12 weeks

  20. Step counts

    Objectively measure activity using FITBIT Charge 5 actigraphy devices. These devices are worn on the wrist and capture total steps.

    Time frame: Change from baseline to endpoint at 12 weeks

  21. C-Reactive Protein

    Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in C-reactive protein in picograms per milliliter in serum from baseline to endpoint at 12 weeks.

    Time frame: Change from baseline to endpoint at 12 weeks

  22. Interleukin-6

    Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in interleukin-6 in picograms per milliliter in serum from baseline to endpoint at 12 weeks.

    Time frame: Change from baseline to endpoint at 12 weeks

  23. Interleukin-10

    Chronic inflammation may be indicative of distress and lead to chronic diseases. The study will examine the change in interleukin-10 in picograms per milliliter in serum from baseline to endpoint at 12 weeks.

    Time frame: Change from baseline to endpoint at 12 weeks

  24. Eforto Grip endurance

    participants will be ask to perform a grip endurance assessment using an Eforto device. The device has a squeezable ball that measures force through changes in air pressure in response to squeezing. Participants are asked to attempt three maximal force tests at 5 seconds each, and then asked to maintain maximal grip for as long as they are able to hold.

    Time frame: Change from baseline to endpoint at 12 weeks

  25. Biosway balance assessment

    Participants are measured for microsway (mm/s) while standing on a Biosway balance device. Participants will be asked to hold balance for 45 seconds while standing comfortably, standing with eyes close, standing with a narrow stance, and standing with a narrow stance with eyes closed.

    Time frame: Change from baseline to endpoint at 12 weeks

  26. Resilience to Blood occlusion

    Participants will be asked to wear a blood pressure cuff while a functional near infrared spectroscopy device measures flow flow in the lower arm. The cuff will be applied to restrict blood flow for 2 minutes, and then released to observe blood oxygenation recovery in the lower arm.

    Time frame: Change from baseline to endpoint at 12 weeks

  27. Stroop Color and Word Test

    Participants will be asked to perform the Stroop color and word test. This test features three sections in which the participant will first read words written in black, then part two name the color of blocks, then the final part name the color of the written words.

    Time frame: Change from baseline to endpoint at 12 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Final data sets will be made available upon specific request and under an authorized Data Use Agreement. This, in addition to the publications being made available via PubMed Central, will enable validation of results by recipients.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After analysis and completion of study along with subsequent publication of results.

Access criteria: After analysis and completion of study along with subsequent publication of results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jul 2027, 41 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 41 months is above that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2022
First posted
Nov 22, 2022
StartActual
Jan 29, 2024
Primary completionEst.
Jul 1, 2027
CompletionEst.
Sep 30, 2027
Last update
Dec 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05625204
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Jan 29, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Dec 12, 2025

Study contacts

Kenneth L Seldeen, PhD
Contact
Kenneth.Seldeen@va.gov
(716) 888-4869
Bruce R Troen, MD
Contact
Bruce.Troen@va.gov
(816) 922-2755
Bruce R. Troen, MD
principal investigator · Kansas City VA Medical Center, Kansas City, MO

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion